Stellungnahme der AIO, DGHO und DGVS zur Nutzenbewertung von Avapritinib bei gastrointestinalen Stromatumoren (GIST)

1. Zusammenfassung

Diese frühe Nutzenbewertung von Avapritinib (Ayvakyt^®) ist das erste Verfahren zu einem neuen Arzneimittel bei gastrointestinalen Stromatumoren (GIST). Avapritinib ist zugelassen zur Therapie von Patienten mit inoperablen oder metastasierten GIST und Nachweis einer PDGFRA-D842V-Mutation. Aufgrund des Orphan-Drug-Status wurde der Bericht vom G-BA erstellt. Subgruppen, zweckmäßige Vergleichstherapie sowie die unterschiedlichen Bewertungsvorschläge sind in [Tab. 1] zusammengefasst.

Publication History

Article published online:
12 April 2021

• Literatur

• 1 Gastrointestinale Stromatumore. Onkopedia Leitlinien von DGHO, OeGHO, SGMO und SGH+SSH, Status, April 2019. https://www.onkopedia.com/de/onkopedia/guidelines/gastrointestinale-stromatumoren-gist/@@guideline/html/index.html
• 2 Falkenhorst J, Hamacher R, Bauer S. New therapeutic agents in gastrointestinal stromal tu- mours. Curr Opin Oncol 2019; 31: 322-328 . doi:10.1097/CCO.0000000000000549
• 3 Hirota S. et al Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580 . doi:10.1126/science.279.5350.577
• 4 Heinrich MC. et al Kinase mutations and imatinib response in patients with metastatic gastroin- testinal stromal tumor. J. Clin. Oncol 2003; 21: 4342-4349 . doi:10.1200/JCO.2003.04.190
• 5 Pogorzelski M, Falkenhorst J, Bauer S. Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments. Curr Opin Oncol 2016; 28: 331-337 . doi:10.1097/CCO.0000000000000303
• 6 Verweij J, Judson I, van Oosterom A. STI571: a magic bullet?. Eur. J. Cancer 2001; 37: 1816-1819 . doi:10.1016/s0959-8049(01)00237-4
• 7 Demetri GD. et al Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med 2002; 347: 472-480 . DOI:10.1056/NEJMoa020461
• 8 Verweij J. et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 2003; 22: 3272-3272
• 9 Blanke CD. et al Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol 2008; 26: 626-632 . doi:10.1200/JCO.2007.13.4452
• 10 Blanke CD. et al Long-term results from a randomized phase II trial of standard- versus higher- dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol 2008; 26: 620-625 . doi:10.1200/JCO.2007.13.4403
• 11 Heinrich MC. et al Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-4774 . doi: 10.1200/JCO.2006.06.2265
• 12 Demetri GD. et al Efficacy and safety of sunitinib in patients with advanced gastrointestinal stro- mal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338 . doi:10.1016/S0140-6736(06)69446-4
• 13 Demetri GD. et al Efficacy and safety of regorafenib for advanced gastrointestinal stromal tu- mours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, pla- cebo-controlled, phase 3 trial. Lancet 2013; 381: 295-302 . doi:10.1016/S0140-6736(12)61857-1
• 14 Yoo C. et al Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha- Mutated Gastrointestinal Stromal Tumors. Cancer Res Treat 2016; 48: 546-552 . doi:10.4143/crt.2015.015
• 15 Heinrich MC. et al PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710 . doi:10.1126/science.1079666
• 16 Corless CL. et al PDGF PDGFRA mutations in gastrointestinal stromal tumors: frequency, spec- trum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-5364 . doi:10.1200/JCO.2005.14.068
• 17 Cassier PA. et al Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012; 18: 4458-4464 . doi:10.1158/1078-0432.CCR-11-3025
• 18 Grunewald S. et al. Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. Cancer Discov 2020;
• 19 Evans EK. et al A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med 2017; 9: 414 . doi:10.1126/scitranslmed.aao1690
• 20 Heinrich MC. et al Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tu- mour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 2020; 21: 935-946 . DOI: 10.1016/S1470-2045(20)30269-2
• 21 Jones RL. et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointesti- nal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer 2021; 145: 132-142
• 22 Cherny NI, Sullivan R, Dafni U. et al A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573 . doi:10.1093/annonc/mdv249
• 23 Cherny NI, Dafni U, Bogaerts J. et al ESMO-Magnitude of Clinical Benefit Scale version1.1. Ann Oncol 2017; 28: 2340-2366 . doi:10.1093/annonc/mdx310